Views & Analysis | Perspectives on pharma industry issues

Digital

Changing Faces: Digital and supplier hires, June and July 20...

The pharma-adjacent tech and services sectors continued to attract experienced leadership talent during June and July.

Patients

Innovation can transform NHS care, but scaling is the missin...

Innovation is already improving care across the NHS, but we are not yet consistently delivering at scale for the benefit of patients

R&D

A physiotherapist assists an ALS patient

Treating mechanisms, not symptoms: ALS R&D today

The ALS clinical trial landscape is characterised by a significant number of active trials and sponsors, including MediciNova's Ph3 with MN-166.

R&D

Why storage resilience will protect the future of CAR-T

Cell and gene therapies are changing the way pharmaceutical organisations think about sample storage.

Patients

Reshaping the future of patient-centric drug development

Strategic partnerships, robust quality systems, and manufacturing know-how will support next-generation therapies with patient-centric designs.

Views & Analysis

UK leaders: Takeda’s Jon Neal

In the first of a new series where we talk to GMs of UK pharma divisions, managing director for Takeda UK & Ireland, Jon Neal, tells us about the Shire acquisition, rare diseases, a

Views & Analysis

How can a fragmented NHS embrace the innovation it needs to ...

Working with the NHS is like doing business with a shoal of fish, each with differing structures, interests and demands.

Views & Analysis

Simple steps to better communicate NHS medicines spend

Leela Barham says that there’s a communication problem when it comes to one of the most important and basic statistics about medicines in the UK: how much the UK spends on them.

Sales & Marketing

Personalisation is the biggest lie brands keep telling

Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.

Sales & Marketing

M&A trends in diagnostics and life sciences tools

The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.

Digital

Changing Faces: Digital and supplier hires, June and July 20...

The pharma-adjacent tech and services sectors continued to attract experienced leadership talent during June and July.

Digital

Australia, AI, and Autolomous

pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.

Market Access

Europe’s new HTA reality: The JCA, one year on

Here, we examine the early realities of JCA implementation, exploring whether the system is delivering greater alignment across European markets.

Market Access

Three separate injections - blue, red, and yellow - take off against black background

Why global pharmaceutical reforms are quietly redirecting ra...

Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs